Description: WST is riding on surging GLP-1 demand and HVP expansion. Yet, pricing pressure, tariff risks and contract manufacturing headwinds cloud the near-term outlook.

Description: In the latest trading session, Cardinal Health (CAH) closed at $208.26, marking a +2.83% move from the previous day.

Description: The healthcare services company says it expects to bring in over $50 billion in specialty revenue in fiscal 2026.

Description: Cardinal Health (NYSE:CAH) today provided an update to its financial outlook for fiscal year 2026 and plans to highlight significant progress with its strategic growth initiatives during the 44th Annual J.P. Morgan Healthcare Conference.

Description: Sterilization services are growing due to regulatory demands and quality standards. Key opportunities include adopting innovative technologies, forming strategic partnerships, and offering flexible service models to enhance compliance and operational efficiency in healthcare, pharmaceuticals, and food sectors. Sterilization Services Market Sterilization Services Market Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The "Sterilization Services Market - Global Forecast 2025-2032" report has been added

Description: In recent days, Cardinal Health has drawn increased attention as analysts upgraded their views and commentators highlighted its role as a major healthcare distributor with a dominant market position and expanding service offerings across pharmaceuticals and medical products. What stands out is how improvements under new management in medical distribution and growth in specialty and biologic therapies are reshaping perceptions of Cardinal Health’s long-term role in the healthcare supply...

Description: Microsoft beat software peers as Azure's 25% cloud share and OpenAI-led AI lift cash flow, despite competition, regulation and rising AI capex.

Description: Cardinal Health, Inc. (NYSE:CAH) is one of the stocks from different market sectors that Jim Cramer commented on. Cramer highlighted the company’s noteworthy performance, as he commented: “The drug distributors continue to relentlessly climb higher. There’s nothing, you know, people hate the pharma middleman. Even the president doesn’t talk, like… them. But I got to […]

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: Dividend-growth stocks like CAH stand out as labor data sends mixed signals, offering income stability and growth amid economic uncertainty.

Description: Cardinal Health, McKesson, and Cencora are showing how scale, specialty focus, and execution can drive market-beating returns despite macro pressure.

Description: What Is Driving the Updated Fair Value Estimate? The slight move in Cardinal Health's fair value estimate, from US$216.60 to US$222.20 per share, reflects how recent research is weighing progress in the business against ongoing risks. On one side, analysts are reacting to stronger views on earnings power tied to specialty growth, the Solaris acquisition, and steadier core Pharma distribution results. On the other side, they are still flagging questions around recovery in the Global Medical...

Description: If you are wondering whether Cardinal Health's share price still offers value after a strong run, this breakdown will help you frame what the current price could be telling you. The stock recently closed at US$201.11, with returns of 1.5% over the last 30 days, a 2.2% decline year to date, and gains of 67.5% over 1 year, 176.1% over 3 years, and 309.3% over 5 years. Recent coverage around Cardinal Health has largely focused on its role as a major healthcare distributor and its exposure to...

Description: Cardinal Health (CAH) is drawing fresh attention as investors reassess its recent share performance alongside the company’s scale, with revenue of US$234.3b and net income of US$1.6b from its diversified healthcare operations. See our latest analysis for Cardinal Health. The latest share price of US$201.11 sits alongside a 30.33% 3‑month share price return and a 67.50% 1‑year total shareholder return, which points to strong recent momentum after a weaker year‑to‑date share price return. If...

Description: PACB introduces CiFi, a new sequencing method designed to expand multiomics capabilities without added hardware.

Description: TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.

Description: Inogen launches Aurora CPAP masks to expand its respiratory care suite and enter the growing sleep apnea market.

Description: In the closing of the recent trading day, Cardinal Health (CAH) stood at $208.48, denoting a +1.47% move from the preceding trading day.

Description: Over the past year, many Cardinal Health, Inc. ( NYSE:CAH ) insiders sold a significant stake in the company which may...

Description: Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2026 on February 5, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.

Description: McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.

Description: Cencora (COR), McKesson (MCK), and Cardinal Health (CAH) performed strongly in 2025, and the drug di

Description: Cardinal Health, Inc. (NYSE:CAH) is included among the 20 Best Performing Dividend Stocks in 2025. Cardinal Health, Inc. (NYSE:CAH)’s market-beating performance reflects a business that has changed direction and executed well. By shifting more of its focus toward higher-margin areas such as specialty pharmaceuticals and managed services, earnings growth has picked up in a meaningful […]

Description: The stock market powered through a year of volatility to mark a strong finish in 2025. While artificial intelligence was a theme that dominated 2025, many winners were instead linked to healthcare and banking. Case in point, CVS Health : The stock was among the names that had their best year in two decades.

Description: Cardinal Health will release its second-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

Description: AMZN, CAH, LRN and EAT stand out with strong interest coverage ratios to help weather 2026's shifting market tides.

Description: Key states, including California and Texas, lead in demand due to advanced healthcare systems and aging populations U.S. Embolic Protection Device Market U.S. Embolic Protection Device Market Dublin, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The "United States Embolic Protection Device Market Report by Product, Application, Material, End-User, States and Company Analysis, 2025-2033" has been added to ResearchAndMarkets.com's offering.United States Embolic Protection Device Market is expected to reach US

Description: Readers hoping to buy Cardinal Health, Inc. ( NYSE:CAH ) for its dividend will need to make their move shortly, as the...

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Description: Cardinal Health leads Zacks' list of large-cap MedTech stocks as AI adoption, robotics and rising procedure volumes set up continued gains in 2026.

Description: Cardinal Health (CAH) has quietly turned into a strong long term performer, with the stock up about 74% this year and roughly 76% over the past year, far outpacing many healthcare peers. See our latest analysis for Cardinal Health. That momentum has been underpinned by solid earnings progress and improving sentiment around Cardinal Health’s execution, with the recent 90 day share price return of 32.71 percent reinforcing a powerful multi year total shareholder return story. If Cardinal...

Description: BDX teams up with the Penn Institute for Immunology and Immune Health to launch a high-parameter immune profiling study.

Description: Four large-cap MedTech leaders, MDT, ISRG, CAH, EW, appear well-positioned to extend their winning streaks in 2026 on resilient procedure demand and innovation.

Description: Cardinal Health (CAH) closed the most recent trading day at $202.95, moving +1.93% from the previous trading session.

Description: Cencora, Inc. (NYSE:COR) is one of the stocks Jim Cramer recently discussed. During the lightning round, a caller inquired about Cramer’s thoughts on the stock, and he commented: “Okay, I like Cencora a lot. But I got to tell you, I think this Cardinal Health’s got them all beat. Jason Hollar is a visionary. I […]

Description: Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy underperformed its benchmark, the Russell Midcap® Growth Index, in the third quarter of 2025, which increased approximately 3%. In addition, please check the fund’s top five holdings […]

Description: For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Description: Ember LifeSciences is moving quickly to turn fresh capital into cold-chain scale. The healthcare logistics technology company has raised $16.5 million in a Series A round to expand deployment of its connected pharmaceutical shipping containers, betting that tighter temperature control and real-time visibility can eliminate one of the industry’s most persistent and costly problems. Temperature […] The post Ember LifeSciences raises $16.5M to scale its cold chain cube appeared first on FreightWave

Description: COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in accordance with the Company’s Articles of Association, the Board has convened and has appointed Ms. Heidi Hunter as new Vice Chair. Ms. Hunter has been a member of the board since 2023. She has over 25 years of industry experience, working across the pharmaceutical value chain, from clinical and comm

Description: BDX expands its BD MAX menu in Europe with IVDR-approved respiratory and STI assays, boosting system utility and reinforcing its diagnostics growth strategy.

Description: Ember LifeSciences, Inc., a leading provider of revolutionary cold chain technology, today announced a $16.5 million Series A funding round, led by Sea Court Capital, with participation from Cardinal Health, Carrier Ventures and other influential investors, including former U.S. Secretary of State Mike Pompeo. The round underscores strong investor confidence in Ember LifeSciences' ability to redefine global medicine distribution through its proprietary temperature control technology.

Description: If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...

Description: When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...

Description: Cardinal Health, Inc. (NYSE:CAH) is included among the 15 Best Stocks to Buy for the Long Term. Barclays analyst Glen Santangelo initiated coverage of Cardinal Health, Inc. (NYSE:CAH) on December 9, giving the stock an Overweight rating and a $243 price target. The firm started its broader view of the US healthcare technology and distribution […]

Description: Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: Cardinal Health has outperformed the broader Nasdaq index over the past year. Moreover, Wall Street analysts remain strongly optimistic about its prospects.

Description: CVS Health issued an update to its full-year guidance Tuesday ahead of its annual investor day, pointing to stronger performance in 2025 than previously expected. CVS now sees total revenue of at least $400 billion, up from $397.3 billion previously and above Wall Street’s forecast for $398.4 billion, according to FactSet. The owner of the drugstore chain and insurance giant Aetna guided for adjusted earnings in the range of $6.60 to $6.70 a share, compared with a prior range of $6.55 to $6.65.

Description: Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI EPI, are now available through Maccabi Healthcare Services, Israel's second-largest health maintenance...

Description: Cardinal Health (CAH) has been on a strong multi year run, and the recent pullback appears more like a pause than a reversal, given its steady revenue and earnings growth. See our latest analysis for Cardinal Health. At around $198.83 per share, recent weakness, including a 7 day share price return of minus 6.33 percent, sits against a powerful backdrop. There is a roughly 68 percent year to date share price return and a 5 year total shareholder return above 300 percent that still points to...

Description: These three dividend stocks offer the best mix of yield, growth, and safety.

Description: BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.

Description: Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: OMCL's expanding SaaS pipeline, global push and solid solvency highlight growth potential despite rising competition.

Description: Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record. In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp. The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.

Description: LTH, CAH, LMAT and FLS emerge as high-coverage-ratio standouts for investors seeking sturdier balance-sheet safety into 2026.

Description: Baxter recalls its Life2000 ventilation system over a serious cybersecurity flaw, pulling the device from the market despite no reported injuries.

Description: Nyxoah secures a finalized CMS rule that sharply lifts 2026 reimbursement for Genio implants, opening fresh momentum for its OSA therapy.

Description: High coverage ratios and earnings growth make CAH, LTH, LMAT and FLS safer investment bets heading into 2026.

Description: Many Cardinal Health, Inc. ( NYSE:CAH ) insiders ditched their stock over the past year, which may be of interest to...

Description: Does Cardinal Health (CAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Description: The average brokerage recommendation (ABR) for Cardinal (CAH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Description: Curious if Cardinal Health is trading at a bargain or getting ahead of itself? Let's get right to what matters for anyone eyeing long-term value. With shares up 3.3% in the last week and a stunning 81.1% year-to-date, Cardinal Health is catching the attention of growth hunters and value seekers alike. Recent news of major contract wins and partnerships in the healthcare supply chain have fueled optimism, suggesting Cardinal Health is strengthening its role in the industry. These developments...

Description: Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Description: Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Description: Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: Dividend growers like NTES and LRCX emerge as defensive standouts as Wall Street rebounds and investors seek stability amid market uncertainty.

Description: Cardinal Health (CAH) shares jumped after the company reported a Q3 earnings beat, delivering revenue and earnings above expectations. EPS rose more than 16% above consensus, sparking renewed optimism among investors. See our latest analysis for Cardinal Health. After its latest earnings beat, Cardinal Health is enjoying a powerful run, with a 31.3% jump in share price over the past month and a remarkable 77.5% year-to-date share price return. Recent momentum is fueled by upbeat quarterly...

Description: Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Description: CVS Health's Aetna debuts an embedded generative AI assistant designed to simplify benefits navigation and elevate the consumer health experience.

Description: These three top-performing stocks have been quietly reaching new highs.

Description: OnPoint Surgical, Inc., a leader in Augmented Reality (AR) and Artificial Intelligence (AI) guidance for spinal interventions, today announced the appointment of Jeremy Laynor as Chief Commercial Officer (CCO).

Description: There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a...

Description: As Wall Street rebounds on hopes of a shutdown resolution, investors turn to value picks like LTH, CAH, MCK and FLS with strong interest coverage ratios.

Description: Does Cardinal Health (CAH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Description: The Biopsy Devices market is projected to reach $4.02 billion by 2033, growing from $2.43 billion in 2024 at a CAGR of 5.75%. This growth is driven by personalized care demand, rising cancer cases, and minimally invasive treatments enhancing patient comfort. Key biopsy devices include needle, punch, and surgical tools for various medical needs. Advancements in biopsy technology ensure precise, early cancer detection and improved patient outcomes. Leading companies like Cardinal Health, Hologic,

Description: Cardinal Health (CAH) shares have climbed over the past month, gaining nearly 29% and catching the eye of many investors. Strong and consistent earnings, along with steady revenue growth, are keeping momentum going for this healthcare distributor. See our latest analysis for Cardinal Health. After a stellar rally in recent weeks, Cardinal Health’s share price has surged to $203.67, pushing its year-to-date share price return to an impressive 72.57%. That momentum follows steady execution and...

Description: It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: According to the average brokerage recommendation (ABR), one should invest in Cardinal (CAH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Description: Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Description: Here is how Alkermes (ALKS) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Description: Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Description: Cardinal Health has experienced robust growth in earnings and topline recently. Observing the momentum, analysts remain strongly bullish on the stock’s prospects.

Description: Cardinal Health’s third quarter performance prompted a positive market reaction, as the company delivered broad-based growth across all five operating segments. Management pointed to robust demand in its Pharmaceutical and Specialty Solutions segment, supported by new customer wins and continued strength in specialty pharmaceuticals, generics, and consumer health. CEO Jason Hollar highlighted meaningful contributions from the company’s MSO (Management Services Organization) platforms and bio-pha

Description: From AI-fueled AppLovin stock to a barrage of defense leaders, the IBD Breakout Stocks Index puts a wide range of names in focus.

Description: Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026.

Description: Key Insights Significantly high institutional ownership implies Cardinal Health's stock price is sensitive to their...

Description: While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Description: Cardinal Health (NYSE: CAH) announced today that it has completed its acquisition of Solaris Health, the country's leading urology MSO. Solaris Health brings more than 750 providers across more than 250 practice locations in 14 states and adds immediate scale to the Urology Alliance within Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance.

Description: We recently published 10 Stocks on Jim Cramer’s Radar. Cardinal Health, Inc. (NYSE:CAH) is one of the stocks Jim Cramer recently discussed. In a show where Cramer spent most of the time discussing Meta and cloud computing, healthcare products and services provider Cardinal Health, Inc. (NYSE:CAH) was a nice shift. Even though the CNBC TV […]

Description: Cardinal Health’s Fair Value Estimate has seen a moderate uplift, increasing from $180.46 to $189.36 per share as a result of shifting analyst views. This change follows strong quarterly performance and new operational guidance, which reinforces optimism in the company’s growth prospects while also highlighting areas for careful observation. Stay tuned to learn how you can remain informed as Cardinal Health’s evolving narrative continues to shape price target updates. Stay updated as the Fair...

Description: Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.

Description: Healthcare distributor and services company Cardinal Health (NYSE:CAH) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 22.4% year on year to $64.01 billion. Its non-GAAP profit of $2.55 per share was 17.3% above analysts’ consensus estimates.

Description: We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Cardinal Health Inc. (NYSE:CAH) is one of the best-performing stocks on Thursday. Cardinal Health propelled to a new 52-week high on Thursday, as investors snapped up shares after posting an impressive earnings performance and raising its growth outlook for fiscal year 2026. At […]

Description: Companies in The News Are: WDC,LLY,IP,CAH

Description: Check out the companies making headlines this week:

Description: Investors were hoping that the company's inaugural earnings release for fiscal 2026 is a harbinger of a prosperous year.

Description: Cardinal Health Inc (CAH) reports strong double-digit growth across all segments, raises full-year EPS guidance, and anticipates continued momentum despite external challenges.

Description: S&P 500 stocks Cardinal Health and C.H. Robinson both had breakouts Thursday after reporting third-quarter earnings. Meanwhile, fellow S&P 500 component Chipotle sank after earnings, receiving several price target cuts.

Description: Shares of healthcare distributor Cencora (NYSE:COR) jumped 3.3% in the morning session after Mizuho analyst Steven Valiquette raised the price target on the company's shares. The price target was increased to $340 from $334, while the firm kept an 'Outperform' rating on the stock. This move signaled continued confidence in Cencora's market performance. Adding to the positive mood in the sector, a key peer, Cardinal Health, reported strong quarterly results and lifted its outlook for the year. Ca

Description: Shares of healthcare distributor and services company Cardinal Health (NYSE:CAH) jumped 16.5% in the morning session after the company reported strong third-quarter 2025 earnings that beat expectations and raised its full-year guidance.

Description: Cardinal Health is charting the next chapter in pharmaceutical logistics with a major investment in modernizing and expanding its distribution network. Designed to improve efficiency, enhance customer responsiveness, and create safer, more supportive workplaces, these upgrades signal a new era in how pharmaceuticals and wellness products move through the supply chain. At the center of […] The post Cardinal Health brings modernization and automation to the pharmaceutical supply chain appeared fir

Description: Cardinal Health (CAH) stock is climbing to a new record high after the company reported earnings results that beat on the top and bottom lines. Cardinal Health CFO Aaron Alt joins Market Catalysts to discuss the earnings print and the company's strategy for future growth. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Pharmaceutical distributor Cardinal Health posted a strong fiscal first quarter and raised its full-year outlook on Thursday, causing shares to surge toward their highest closing level on record. For fiscal 2026, Cardinal Health expects adjusted earnings in the range of $9.65 to $9.85 a share. Analysts polled by FactSet were looking for $9.44.

Description: Cardinal Health (NYSE: CAH) delivered a commanding first quarter for fiscal 2026, beating both earnings and revenue expectations by wide margins while raising full-year guidance. The stock climbed 1% in early trading as investors digested results that extend a perfect eight-quarter beat streak. A Quarter of Broad Execution Non-GAAP earnings per share came in at ... Cardinal Health Surges After Reporting Strong Q1 Financial Results

Description: Cardinal Health delivered a strong Q1 beat and lifted its 2026 EPS outlook, fueled by broad-based growth and rising profits across all business segments.

Description: While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Cardinal (CAH) delivered earnings and revenue surprises of +15.38% and +8.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Healthcare distributor and services company Cardinal Health (NYSE:CAH) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 22.4% year on year to $64.01 billion. Its non-GAAP profit of $2.55 per share was 17.3% above analysts’ consensus estimates.

Description: The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $2.21 per share. The prescription drug distributor posted revenue of $64.01 billion in the period, which also beat Street forecasts.

Description: Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2026 revenues of $64 billion, an increase of 22% from the first quarter of fiscal year 2025. First quarter GAAP operating earnings increased 18% to $668 million and GAAP diluted earnings per share (EPS) increased 11% to $1.88. First quarter non-GAAP operating earnings increased 37% to $857 million, driven by segment profit growth across all five of the company's operating segments. Non-GAAP diluted EPS increased 36% to $2.55, r

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: In the past week, Cardinal Health announced it will report its Q3 earnings, with analysts projecting a sizable revenue increase to US$59.36 billion and adjusted earnings of US$2.17 per share, reversing a decline in the prior year quarter. An interesting insight is that Cardinal Health's role in specialized healthcare logistics, such as cell and gene therapy distribution, is gaining prominence as the industry shifts toward advanced therapies and complex supply chains. To assess the...

Description: Many Cardinal Health, Inc. ( NYSE:CAH ) insiders ditched their stock over the past year, which may be of interest to...

Description: Healthcare distributor and services company Cardinal Health (NYSE:CAH) will be announcing earnings results this Thursday before the bell. Here’s what you need to know.

Description: Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cardinal (CAH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Description: The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California

Description: Trying to decide whether to hold, buy, or walk away from Cardinal Health stock? You’re not alone, and for good reason. After all, the company’s shares have defied gravity lately, boasting a one-year surge of 48.1% and a remarkable 301.6% gain over the past five years. Even this year alone, Cardinal Health is already up by 37.2%. Clearly, something more than luck is at play here. If you’ve been tracking recent moves, you’ve probably noticed the healthy 3.5% gain in the past week, capping off a...

Description: In the closing of the recent trading day, Cardinal Health (CAH) stood at $161.89, denoting a +1.72% move from the preceding trading day.

Description: CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.

Description: Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Description: Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Radiopharmaceutical CDMO Market size & share revenue was valued at approximately USD 2.95 Billion in 2024 and is expected to reach USD 3.1 Billion in 2025 and is expected to reach around USD 7.2 Billion by 2034, at a CAGR of 9.3% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are NorthStar Medical Radioiso

Description: Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Aspirin Market size & share revenue was valued at approximately USD 2.52 Billion in 2024 and is expected to reach USD 2.60 Billion in 2025 and is expected to reach around USD 3.40 Billion by 2034, at a CAGR of 3.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Bayer AG, Suzhou Kuacai Information Techn

Description: Cardinal Health shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Earlier this week, Cycle Pharmaceuticals announced the launch of PHYRAGO, a new oncology therapy for leukemia, developed with Handa Therapeutics and made exclusively available in the US through Onco360® and a specialty distribution network that includes McKesson. This collaboration provides McKesson with a valuable commercial opportunity as an exclusive distributor for a newly introduced specialty oncology product in high-need therapeutic areas. We'll explore how McKesson's participation in...

Description: CVS Pharmacy completes the Rite Aid deal, adding 63 stores, 626 pharmacies and nine million patients to its national care network.